1.Non-invasive markers for staging fibrosis in patients with chronic hepatitis Delta
Sarantuya G ; Sumiya D ; Selenge J ; Uranbailgal E ; Otgonbayar R ; Munkhbat B ; Bira N
Mongolian Medical Sciences 2021;195(1):18-24
Introduction:
Determining stages of liver fibrosis in chronic liver disease is essential for clinical practice such as
decision making on medical treatment, setting the interval of follow-up examination for its complication,
screening intervals for hepatocellular carcinoma.
Goal:
We compared non-invasive fibrosis markers among the patients with chronic hepatitis Delta.
Materials and Methods:
Totally 70 patients with chronic hepatitis D enrolled into this study. The blood samples were examined
for complete blood count, liver function test and serum M2BPGi level. Non-invasive markers such
as AAR, APRI, Fib-4 scores were calculated. Those with AAR >1, APRI >0.7, FIB-4 >1.45 were
considered with advanced fibrosis. All patients underwent liver stiffness measurement using FibroScan
M2 probe. The cutoff values of FibroScan for advanced fibrosis were 9 kPa for patient with normal
transaminase level and 11 kPa for patients with elevated transaminase.
Results:
Advanced fibrosis was observed in 25.7%, 38.6% and 38.6% by AAR, APRI and Fib-4 score,
respectively. When cut-off levels of serum M2BPGi for advanced fibrosis was 2.2 COI, 35.7% had
advanced fibrosis. FibroScan tests showed 34.4% had advanced fibrosis. The AUROC of M2BPGi
were 0.894 and 0.827 for predicting advanced fibrosis and liver cirrhosis.
Conclusion
Serum M2BPGi and FibroScan would be reliable diagnostic tool for identifying liver
fibrosis in Mongolian patients with chronic hepatitis D.